Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Δ24RGD

被引:27
作者
Majem, M. [1 ]
Cascallo, M. [1 ]
Bayo-Puxan, N. [1 ]
Mesia, R. [1 ]
Germa, J. R. [1 ]
Alemany, R. [1 ]
机构
[1] Hosp Llobregat, IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Spain
关键词
oncolysis; adenovirus; insulator;
D O I
10.1038/sj.cgt.7700940
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We previously described Ad-Delta 24RGD as an enhanced-infectivity oncolytic adenovirus that targets tumors with an impaired RB pathway. The common alteration of this pathway in cancer eliminates the interaction of pRB with E2F and releases free E2F to activate E2F-responsive promoters, including the E2F-1 promoter. To improve the selectivity towards RB pathway-defective tumors and reduce the toxicity of Ad-Delta 24RGD we aimed to control E1A-Delta 24 expression under the E2F-1 promoter. A polyA signal was inserted upstream of the E2F-1 promoter to stop transcription initiated at the adenovirus ITR and packaging signal. The human myotonic dystropy locus insulator (DM-1) was also located between the E1a enhancers and the E2F-1 promoter to further insulate the promoter. The Ad-Delta 24RGD derivative containing these insulation sequences expressed less E1a-Delta 24 in normal cells and resulted less toxic while maintaining the potent oncolytic activity of the parental virus. These results demonstrate that the human DM-1 inslulator can function in an adenovirus context to maintain heterologous promoter selectivity. The new oncolytic adenovirus presented here may represent a valuable therapeutic option for a broad range of tumors with a deregulated E2F/pRB pathway.
引用
收藏
页码:696 / 705
页数:10
相关论文
共 48 条
[1]   Blood clearance rates of adenovirus type 5 in mice [J].
Alemany, R ;
Suzuki, K ;
Curiel, DT .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2605-2609
[2]   Human papillomavirus E6E7-mediated adenovirus cell killing:: Selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes [J].
Balagué, C ;
Noya, F ;
Alemany, R ;
Chow, LT ;
Curiel, DT .
JOURNAL OF VIROLOGY, 2001, 75 (16) :7602-7611
[3]   The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors [J].
Bernt, KM ;
Ni, SH ;
Li, ZY ;
Shayakhmetov, DM ;
Lieber, A .
MOLECULAR THERAPY, 2003, 8 (05) :746-755
[4]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[5]   Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors [J].
Buvoli, M ;
Langer, SJ ;
Bialik, S ;
Leinwand, LA .
GENE THERAPY, 2002, 9 (03) :227-231
[6]  
Cascalló M, 2003, CANCER RES, V63, P5544
[7]   Adenovirus-mediated gene transfer into human hepatocytes: Analysis of the biochemical functionality of transduced cells [J].
Castell, JV ;
Hernandez, D ;
GomezFoix, AM ;
Guillen, I ;
Donato, T ;
GomezLechon, MJ .
GENE THERAPY, 1997, 4 (05) :455-464
[8]   An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism [J].
Dmitriev, I ;
Krasnykh, V ;
Miller, CR ;
Wang, MH ;
Kashentseva, E ;
Mikheeva, G ;
Belousova, N ;
Curiel, DT .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9706-9713
[9]   INFECTION OF MOUSE-LIVER BY HUMAN ADENOVIRUS TYPE-5 [J].
DUNCAN, SJ ;
GORDON, FCA ;
GREGORY, DW ;
MCPHIE, JL ;
POSTLETHWAITE, R ;
WHITE, R ;
WILLCOX, HNA .
JOURNAL OF GENERAL VIROLOGY, 1978, 40 (JUL) :45-61
[10]   The regulation of E2F by pRB-family proteins [J].
Dyson, N .
GENES & DEVELOPMENT, 1998, 12 (15) :2245-2262